Research programme: anti-infectives - Bristol-Myers Squibb

Drug Profile

Research programme: anti-infectives - Bristol-Myers Squibb

Alternative Names: Antibacterials research programme - Bristol-Myers Squibb; Antifungals research programme - Bristol-Myers Squibb; BMS 249524; BMS 411886; BMS 461996; Isoxazolinone antibacterials research programme - Bristol-Myers Squibb; Nocathiacin I

Latest Information Update: 15 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Isoxazoles; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Mycoses

Most Recent Events

  • 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
  • 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals
  • 09 May 2001 Preclinical development for Bacterial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top